Tocagen Announces Presentations at SNO 2014 Annual Conference

Tocagen to Present Toca 511 Data at the 19th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology

MIAMI – November 11, 2014 — Tocagen Inc., a clinical-stage selective cancer immunotherapy company, today announced podium and poster presentations of multiple clinical and preclinical studies of Toca 511 at the 19th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO), to be held Nov. 13-16, 2014, in Miami.

Podium presentations are as follows:

Abstract #: IT-05
Title: “Administration of Toca 511 to subjects with recurrent HGG undergoing repeat resection”
Time: Saturday, Nov. 15, at 11:30 a.m. ET
Delivered by: Tim Cloughesy, M.D., director of the University of California, Los Angeles (UCLA) Neuro-Oncology Program
Location: Americana 3

Abstract #: ET-60
Title: “Enhanced therapeutic efficacy of prodrug activator gene therapy with a non-lytic retroviral replicating vector (Toca 511) combined with radiation therapy in experimental glioma”
Time: Saturday, Nov. 15, at 8:20 a.m. ET
Delivered by: Masamichi Takahashi, M.D., Ph.D., from the department of neurosurgery and neuro-oncology, National Cancer Center in Tokyo, and the David Geffen School of Medicine at UCLA
Location: Poinciana 1,2,3,4

Posters will be presented on Friday, Nov. 14, at 7:30 p.m. ET in Americana 4 and are as follows:

Abstract #: AT-29
Title: “Intravenous administration of Toca 511 in patients with recurrent glioblastoma”
Presented by: Steven Kalkanis, M.D., chair of the department of neurosurgery and co-director of the Neuroscience Institute, Henry Ford Hospital

Abstract #: AT-02
Title: “Intratumoral delivery of the retroviral replicating vector (RRV) Toca 511 in subjects with recurrent high grade glioma: interim report of Phase 1 study (NCT 01156584)”
Presented by: Manish Aghi, M.D., associate professor of neurological surgery, University of California, San Francisco

Abstract #: ET-23

Title: “Therapeutic efficacy of retroviral replicating vectors in a human breast cancer CNS metastasis model”
Presented by: Akihito Inagaki, Ph.D., from the department of cell biology, University of Miami, and the David Geffen School of Medicine at UCLA

Abstract #: ET-13
Title: “Retroviral replicating vector (RRV)-mediated prodrug activator gene therapy with codon-optimized nitroreductase”
Presented by: Sara Collins, Ph.D., from the department of cell biology, University of Miami, and the David Geffen School of Medicine at UCLA

About Tocagen
Tocagen is a clinical-stage selective cancer immunotherapy company pursuing discovery, development and commercialization of gene therapy drugs using a novel retroviral replicating vector platform. These therapies are designed to help patients fight their cancer by locally activating their immune system selectively against their cancer, with subsequent systemic benefit.

Tocagen has received grant support from leading brain cancer foundations, including Accelerate Brain Cancer Cure (ABC2), National Brain Tumor Society (NBTS), American Brain Tumor Association (ABTA), Musella Foundation and Voices Against Brain Cancer (VABC). For more information about Tocagen or Toca 511 & Toca FC please visit www.tocagen.com or www.clinicaltrials.gov using the identifier NCT01470794, NCT01156584 or NCT01985256.

About Toca 511 & Toca FC
Toca 511 & Toca FC, the company’s lead investigational combination product, is being evaluated in three clinical trials in patients with recurrent high grade glioma, including glioblastoma (GBM). Toca 511 & Toca FC is designed to have a dual mechanism of action. Toca 511 delivers a prodrug-activating gene selectively to cancer cells. Then the prodrug-activating enzyme produced in the cancer cell activates orally administered Toca FC, an extended-release formulation of 5-fluorocytosine (5-FC), into a powerful antimetabolite, 5-FU, selectively in the cancer. The production of 5-FU locally kills tumor cells, which leads to prolonged and selective anticancer immune responses in animal models. Data from ongoing clinical trials show encouraging safety and tolerability, antitumor activity, and evidence to support the proposed mechanism of action. Based on these data the company is now planning to commence late stage clinical trials in patients with high grade glioma.